Improving quality of life in hypertension management using a fixed-dose combination of olmesartan and amlodipine in primary care

Expert Opinion on Pharmacotherapy

Volumn 11, Issue 17, 2010, Pages 2779-2790

  Bramlage, Peter ^a   Wolf, Wolf Peter ^b   Fronk, Eva Maria ^b   Stuhr, Thomas ^b   Erdlenbruch, Wolfhard ^b   Wasem, Jrgen ^c   Ketelhut, Reinhard ^d   Schmieder, Roland E ^e  

^a Institute for Cardiovascular Pharmacology and Epidemiology   (Germany)

^b DAIICHI SANKYO CO   (Japan)

^c UNIVERSITY OF DUISBURG ESSEN   (Germany)

^d HUMBOLDT UNIVERSITY   (Germany)

^e UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

Amlodipine; Antihypertensive treatment; Olmesartan; Quality of life; Short Form 12

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; OLMESARTAN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; FEMALE; FOLLOW UP; HEART RATE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; MULTICENTER STUDY; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; PRIMARY MEDICAL CARE; PULSE PRESSURE; QUALITY OF LIFE; SHORT FORM 12; SYSTOLIC BLOOD PRESSURE; UNSPECIFIED SIDE EFFECT;

AGED; AMLODIPINE; ANTIHYPERTENSIVE AGENTS; DIASTOLE; DRUG COMBINATIONS; FEMALE; HEART RATE; HUMANS; HYPERTENSION; IMIDAZOLES; MALE; MIDDLE AGED; PRIMARY HEALTH CARE; QUALITY OF LIFE; QUESTIONNAIRES; SYSTOLE; TETRAZOLES;

EID: 78149463820     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2010.521499     Document Type: Article

References (48)

1. Kullman S, Svardsudd K. Differences in perceived symptoms/quality of life in untreated hypertensive and normotensive men. Scand J Prim Health Care Suppl 1990;1:47-53
2. Battersby C, Hartley K, Fletcher AF, et al. Quality of life in treated hypertension: a case-control community based study. J Hum Hypertens 1995;9:981-6
3. Siegrist J, Matschinger H, Motz W. Untreated hypertensives and their quality of life. J Hypertens Suppl 1987;5:S15-20
4. Kjellgren KI, Ahlner J, Dahlof B, et al. Perceived symptoms amongst hypertensive patients in routine clinical practice - a population-based study. J Intern Med 1998;244:325-32
5. Muller A, Montoya P, Schandry R, et al. Changes in physical symptoms, blood pressure and quality of life over 30 days. Behav Res Ther 1994;32:593-603
6. Schoenberger JA, Croog SH, Sudilovsky A, et al. Self-reported side effects from antihypertensive drugs. A clinical trial. Quality of Life Research Group. Am J Hypertens 1990;3:123-32
7. Bramlage P, Hasford J. Blood pressure reduction, persistence and costs in the evaluation of antihypertensive drug treatment - a review. Cardiovasc Diabetol 2009;8:18
8. Law M, Wald N, Morris J. Lowering blood pressure to prevent myocardial infarction and stroke: a new preventive strategy. Health technology assessment (Winchester, England) 2003;7:1-94
9. Oparil S, Williams D, Chrysant SG, et al. Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertens (Greenwich) 2001;3:283-91, 318
10. Schmidt AC, Bramlage P, Lichtenthal A, et al. Socio-economic status and the therapeutic effectiveness of antihypertensive treatment - the design of the LEO study. Curr Med Res Opin 2007;23:1987-95
11. Nissen SE, Tuzcu EM, Libby P, et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 2004;292:2217-25
12. Wang JG, Li Y, Franklin SS, et al. Prevention of stroke and myocardial infarction by amlodipine and Angiotensin receptor blockers: a quantitative overview. Hypertension 2007;50:181-8
13. Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366:895-906
14. Barrios V, Boccanelli A, Ewald S, et al. Efficacy and tolerability of olmesartan medoxomil in patients with mild to moderate essential hypertension: the OLMEBEST Study. Clin Drug Investig 2007;27:545-58
15. Charles JA, Jotkowitz S, Byrd LH. Prevention of migraine with olmesartan in patients with hypertension/ prehypertension. Headache 2006;46:503-7
16. Schmidt AC, Bramlage P, Limberg R, et al. Quality of life in hypertension management using olmesartan in primary care. Expert Opin Pharmacother 2008;9:1641-53
17. Pessina AC, Boari L, De Dominicis E, et al. Efficacy, tolerability and influence on quality of life of nifedipine GITS versus amlodipine in elderly patients with mild-moderate hypertension. Blood Press 2001;10:176-83
18. Testa MA, Turner RR, Simonson DC, et al. Quality of life and calcium channel blockade with nifedipine GITS versus amlodipine in hypertensive patients in Spain. Gastrointestinal therapeutic system. J Hypertens 1998;16:1839-47
19. Zanchetti A, Omboni S, La Commare P, et al. Efficacy, tolerability, and impact on quality of life of long-term treatment with manidipine or amlodipine in patients with essential hypertension. J Cardiovasc Pharmacol 2001;38:642-50
20. Omvik P, Thaulow E, Herland OB, et al. Double-blind, parallel, comparative study on quality of life during treatment with amlodipine or enalapril in mild or moderate hypertensive patients: a multicentre study. J Hypertens 1993;11:103-13
21. Chrysant SG, Melino M, Karki S, et al. The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study. Clin Ther 2008;30:587-604
22. Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008;359:2417-28
23. Bramlage P, Wolf W-P, Stuhr T, et al. Effectiveness and tolerability of a fixed dose combination of olmesartan and amlodipine in clinical practice. Vasc Health Risk Manag 2010;6:803-11
24. Ware J Jr, Kosinski M, Keller SD. A 12-Item short-form health survey: construction of scales and preliminary tests of reliability and validity. Med Care 1996;34:220-33
25. Pickard AS, Johnson JA, Penn A, et al. Replicability of SF-36 summary scores by the SF-12 in stroke patients. Stroke 1999;30:1213-17
26. Bullinger M, Kirchberger I. SF-36 Fragebogen zum Gesundheitszustand. 1998
27. Ellert U, Bellach BM. Der SF-36 im Bundes-Gesundheitssurvey - Beschreibung einer aktuellen Normstichprobe [SF-36 Questionnaire in the Federal Health Survey - Description]. Gesundheitswesen 1999;61:184-90
28. Guyatt GH, Feeny DH, Patrick DL. Measuring health-related quality of life. Ann Intern Med 1993;118:622-9
29. Fitzpatrick R, Fletcher A, Gore S, et al. Quality of life measures in health care. I: Applications and issues in assessment. BMJ 1992;305:1074-7
30. Beto JA, Bansal VK. Quality of life in treatment of hypertension. A metaanalysis of clinical trials. Am J Hypertens 1992;5:125-33
31. Weinberger M, Kirkman MS, Samsa GP, et al. The relationship between glycemic control and health-related quality of life in patients with non-insulin-dependent diabetes mellitus. Med Care 1994;32:1173-81
32. Cote I, Gregoire JP, Moisan J, et al. Quality of life in hypertension: the SF-12 compared to the SF-36. Can J Clin Pharmacol 2004;11:e232-8
33. Okano Y, Tamura K, Masuda S, et al. Effects of angiotensin II receptor blockers on the relationships between ambulatory blood pressure and anti-hypertensive effects, autonomic function, and health-related quality of life. Clin Exp Hypertens 2009;31:680-9
34. Okano Y, Tamura K, Kuji T, et al. Effects of angiotensin II receptor blockers on relationships between 24-hour blood pressure, autonomic function, and health-related QOL. Clin Exp Hypertens 2009;31:250-8
35. Badia X, Gutierrez F, Wiklund I, et al. Validity and reliability of the Spanish version of the Psychological General Well-Being Index. Qual Life Res 1996;5:101-8
36. Rake EC, Breeze E, Fletcher AE. Quality of life and cough on antihypertensive treatment: a randomised trial of eprosartan, enalapril and placebo. J Hum Hypertens 2001;15:863-7
37. Tedesco MA, Ratti G, Mennella S, et al. Comparison of losartan and hydrochlorothiazide on cognitive function and quality of life in hypertensive patients. Am J Hypertens 1999;12:1130-4
38. Van Bortel LM, Bulpitt CJ, Fici F. Quality of life and antihypertensive effect with nebivolol and losartan. Am J Hypertens 2005;18:1060-6
39. Weber MA, Bakris GL, Neutel JM, et al. Quality of life measured in a practice-based hypertension trial of an angiotensin receptor blocker. J Clin Hypertens (Greenwich) 2003;5:322-9
40. Dahlof B, Lindholm LH, Carney S, et al. Main results of the losartan versus amlodipine (LOA) study on drug tolerability and psychological general well-being. LOA Study Group. J Hypertens 1997;15:1327-35
41. Dahlof B, Degl Innocenti A, Elmfeldt D, et al. Felodipine-metoprolol combination tablet: maintained health-related quality of life in the presence of substantial blood pressure reduction. Am J Hypertens 2005;18:1313-19
42. Takase B, Takeishi Y, Hirai T, et al. Comparative effects of amlodipine monotherapy and combination therapy with betaxolol on cardiac autonomic nervous activity and health-related quality of life in patients with poorly controlled hypertension. Circ J 2008;72:764-9
43. Fogari R, Preti P, Zoppi A, et al. Effect of valsartan and atenolol on sexual behavior in hypertensive postmenopausal women. Am J Hypertens 2004;17:77-81
44. Tsuji H, Larson MG, Venditti FJ Jr, et al. Impact of reduced heart rate variability on risk for cardiac events. The Framingham Heart Study. Circulation 1996;94:2850-5
45. Bangalore S, Kamalakkannan G, Parkar S, et al. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007;120:713-19
46. Pedrinelli R, DellOmo G, Mariani M. Calcium channel blockers, postural vasoconstriction and dependent oedema in essential hypertension. J Hum Hypertens 2001;15:455-61
47. Weir MR. Incidence of pedal edema formation with dihydropyridine calcium channel blockers: issues and practical significance. J Clin Hypertens (Greenwich) 2003;5:330-5
48. Chrysant SG, Oparil S, Melino M, et al. Efficacy and safety of long-term treatment with the combination of amlodipine besylate and olmesartan medoxomil in patients with hypertension. J Clin Hypertens (Greenwich) 2009;11:475-82